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Median age (IQR) 45 (34-57) 56 (45-64) 
Male sex (%) 3,482 (62%) 3,514 (73%) 
Positive HBeAg (%) 2,032 (37%) 1,468 (31%) 
HBV DNA 
(IU/ml) 
Undetectable 692 (12%) 3,080 (64%) 
< 2,000 1,550 (27%) 1,256 (26%) 
2,000–19,999 506 (9%) 155 (3%) 
20,000-199,999 448 (8%) 116 (3%) 
≥ 200,000 2,395 (43%) 199 (4%) 
HBcrAg (log 
U/ml) 
Undetectable 1,811 (32%) 1,269 (26%) 
3.0 – 3.9 832 (15%) 1,074 (22%) 
4.0 – 4.9 423 (8%) 1,071 (22%) 
5.0 – 6.9 903 (16%) 1,201 (25%) 
≥ 7.0 1,622 (29%) 191 (4%) 
HBV genotype 
A 287 (6%) 74 (2%) 
B 1,027 (20%) 429 (11%) 
C 2,861 (57%) 3,392 (84%) 
D 538 (11%) 67 (2%) 
E 270 (5%) 34 (<1%) 
F 21 (1%) 61 (1%) 
G 2 (<1%) 1 (<1%) 
H 3 (<1%) 0 (0%) 
Co-infection 
HIV 10/2,240 (<1%) 16/991 (2%) 
HCV 49/4,465 (1%) 7/1,411 (<1%) 
HDV 156/2,031 (8%) 12/762 (2%) 
 
HBcrAg: hepatitis B core-related antigen; HBeAg: hepatitis B e antigen; HBV: hepatitis B virus; 





Table 3. Performance of serum HBcrAg to diagnose clinically important HBV DNA levels in untreated patients* 
 HBV DNA ≥2,000 IU/ml HBV DNA ≥20,000 IU/ml HBV DNA ≥200,000 IU/ml 




(0.84-0.94) 84.5 84.5 84.5 N/A 
0.95 
(0.93-0.97) 89.3 89.6 89.5 N/A 
0.96 




(0.83-0.93) 85.2 84.7 85.0 N/A 
0.95 
(0.93-0.97) 90.4 91.9 91.1 N/A 
0.96 





(0.85-0.96) 87.3 78.5 84.4 N/A 
0.96 
(0.93-0.99) 92.2 87.1 90.0 N/A 
0.98 





(0.84-0.94) 84.9 82.7 84.1 0.6 
0.94  
(0.92-0.97) 88.5 89.1 88.8 0.3 
0.96  
(0.93-0.98) 90.1 89.0 89.5 0.1 Females 
(2,098) 
0.87  
(0.81-0.93) 83.5 87.0 85.1 
0.96  
(0.94-0.98) 91.9 91.8 91.8 
0.98  






(0.87-0.98) 91.6 64.4 85.9 0.2 
0.97  
(0.94-1.00) 95.0 81.6 91.1 0.2 
0.98  




(0.81-0.93) 83.1 86.4 84.5 
0.95  
(0.92-0.97) 89.2 91.2 90.2 
0.96  





(0.83-0.94) 84.8 87.2 85.7 
0.9 
0.94  
(0.92-0.97) 89.0 90.1 89.5 
0.5 
0.96  
(0.93-0.98) 89.6 90.0 89.8 
0.5 Europe (1,047) 
0.86  
(0.69-1.00) 83.4 74.7 80.0 
0.98  
(0.93-1.00) 95.4 91.4 93.4 
0.99  




(0.77-0.93) 80.2 83.9 83.0 
0.92  
(0.85-0.99) 89.8 89.8 89.8 
0.94  





(0.87-0.96) 97.9 23.4 95.0 
<0.01 
0.87  
(0.82-0.93) 98.8 21.0 93.3 0.7 
0.86  
(0.81-0.91) 98.1 25.6 88.7 0.08 Negative 
(3,407) 
0.74  
(0.63-0.85) 66.0 87.2 79.4 
0.89  
(0.84-0.95) 77.2 94.5 90.3 
0.93  






(0.71-0.94) 75.8 89.8 82.5 
0.7 
0.93  
(0.84-1.00) 85.6 93.3 90.4 
0.9 
0.95  
(0.87-1.00) 90.5 92.9 92.2 
0.9 B (1,027) 
0.87  
(0.79-0.96) 85.0 93.6 88.5 
0.95  
(0.91-0.99) 91.6 94.8 93.2 
0.97  




(0.85-0.96) 86.8 84.6 86.0 
0.95  
(0.92-0.99) 91.0 88.4 89.9 
0.96  








(0.55-1.00) 78.2 63.6 70.8 
0.96  
(0.89-1.00) 91.4 89.4 90.1 
0.98  




(0.60-1.00) 85.4 85.9 85.7 
0.95  
(0.91-0.99) 94.6 87.8 89.8 
0.96  





(0.82-1.00) 89.8 78.3 81.6 0.5 
0.97  
(0.92-1.00) 94.8 82.9 85.1 0.5 
0.98  
(0.94-1.00) 95.6 84.5 85.6 0.2 Negative 
(4,416) 
0.89  
(0.83-0.94) 84.9 85.4 85.1 
0.95  
(0.93-0.98) 90.3 90.6 90.4 
0.96  





(0.81-0.96) 85.3 83.4 83.7 0.9 
0.96  
(0.93-0.99) 92.0 89.3 89.5 0.9 
0.97  
(0.94-0.99) 93.3 90.3 90.4 0.9 Negative 
(1,875) 
0.89  
(0.84-0.94) 85.2 88.4 86.1 
0.95  
(0.93-0.98) 90.8 91.2 91.0 
0.97  
(0.95-0.99) 91.7 91.0 91.4 
 
* Optimal cut-offs for serum HBcrAg derived from the derivation set were 3.6 log U/ml to diagnose HBV DNA ≥2,000 IU/ml, 4.5 log U/ml for ≥20,000 
IU/ml, and 5.3 log U/ml for ≥200,000 IU/ml. 
† p for interaction for AUROC 
AUROC: area under the receiver operating characteristic curve; CC, correctly classified; CI: confidence interval; HBcrAg: hepatitis B core-related antigen; 
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Abstract (<260 words) 
Background and Aims 
To eliminate HBV infection, scale-up of testing and treatment in resource-limited countries is crucial. 
However, access to nucleic acid testing (NAT) to quantify HBV DNA, an essential test to examine 
treatment eligibility, remains severely limited. We assessed the performance of novel immunoassay, 
HBV core-related antigen (HBcrAg), as a low-cost (US$<15/assay) alternative to NAT to indicate 
clinically important high viremia in chronic HBV patients infected with different genotypes. 
Methods 
We searched Medline/Embase/Scopus/Web of Science until 06/27/2018. Three reviewers 
independently selected studies measuring HBV DNA and HBcrAg in the same blood samples. We 
contacted authors to provide individual participant data (IPD). We randomly allocated each IPD to 
derivation or validation cohort. We applied optimal HBcrAg cut-offs derived from the derivation set to 
the validation set to estimate sensitivity/specificity.  
Results 
Of 74 eligible studies, IPD were successfully obtained for 60 (81%). Meta-analysis included 5,591 
IPD without antiviral therapy and 4,806 under antivirals. In untreated patients, pooled area under the 
receiver operating characteristic curve and optimal cut-offs (log U/ml) were: 0.88 (95%CI: 0.83-0.94) 
and 3.6 to diagnose HBV DNA level ≥2,000 IU/ml; and 0.96 (0.94-0.98) and 5.3 for ≥200,000 IU/ml, 
respectively. In the validation set, the sensitivity and specificity were 85.2% and 84.7% for ≥2,000 
IU/ml, and 91.8% and 90.5% for ≥200,000 IU/ml, respectively. The performance did not vary by HBV 
genotypes. In patients under anti-HBV therapy the correlation between HBcrAg and HBV DNA was 
poor.  
Conclusion 
HBcrAg might be useful serological marker to indicate clinically important high viremia in treatment-
naïve HBV-infected patients.  
Keywords 












Viral hepatitis, the 7th leading cause of death worldwide, kills more people than any of the major 
infectious diseases (HIV/tuberculosis/malaria), and is now targeted by the United Nations Sustainable 
Development Goals.1 Hepatitis B virus (HBV) infection accounts for more than half of these hepatitis-
related deaths. In 2016, the World Health Organization (WHO) developed a global strategy to 
eliminate hepatitis B as a public health threat, and one of the goals is to increase antiviral treatment 
uptake from 8% in 2015 to 80% by 2030 in people with chronic HBV infection (CHB) who are 
eligible for antiviral therapy.1 To achieve this objective, it is urgent to scale up both hepatitis B surface 
antigen (HBsAg) screening and clinical staging for people carrying HBsAg to assess their eligibility 
for anti-HBV therapy. 
 
Following a positive HBsAg screening test, it is essential to quantify serum HBV DNA levels using 
nucleic acid test (NAT) to decide whether antiviral treatment should be initiated. According to the 
international guidelines, having high viremia (≥2,000 or ≥20,000 IU/ml) in the presence of liver 
inflammation or fibrosis indicates treatment eligibility.2–5 Recently, the cut-off of ≥200,000 IU/ml has 
been applied to select pregnant women who would benefit most from antiviral prophylaxis to prevent 
mother-to-child transmission.3,4 However, real-time polymerase chain reaction (RT-PCR), a standard 
NAT assay to quantify HBV DNA levels, is not affordable and accessible in many low- and middle-
income countries (LMICs) because of its high cost (US$ 60-200/assay) and strict laboratory 
requirements for sophisticated equipment and well-trained staff.1 Since the vast majority (>95%) of 
people with CHB live in LMICs,6 the limited access to RT-PCR represents a major obstacle to achieve 
global hepatitis elimination, and WHO fully recognizes an urgent need for a low-cost simple assay to 
measure active HBV replication.2  
 
Likewise, the limited access to NAT to diagnose chronic hepatitis C virus (HCV) infection remains an 
important barrier to expand anti-HCV treatment in LMICs. A systematic review was therefore 
undertaken to evaluate the accuracy of an immunoassay (HCV core antigen (HCVcAg)) as a low-cost 





these data WHO now recommends the use of HCVcAg for the detection of HCV RNA when NAT is 
not accessible.2  
 
HBV core-related antigen (HBcrAg) is a novel immunoassay to measure HBV replication. The assay 
quantifies HBV core antigen (HBcAg), e antigen (HBeAg) as well as p22cr and c-terminal modified 
HBcAg contained in the empty particle fraction in blood regardless of anti-HBc or anti-HBe 
antibodies.8,9 A close correlation between serum HBcrAg levels and HBV DNA levels has been 
suggested in treatment-naïve patients with CHB.10–14 Moreover, a correlation of serum HBcrAg levels 
with intrahepatic covalently closed circular DNA (cccDNA), a transcriptional template of HBV, has 
been also observed in several Asian and European studies.10,11,15,16 Because this immunoassay is 
cheaper (US$ <15/assay) and simpler than the RT-PCR, HBcrAg may potentially represent an 
attractive alternative to HBV DNA PCR in resource-limited countries, and also for hard-to-reach 
populations living in high-income countries. However, its capability to discriminate between high and 
low serum HBV DNA levels across different HBV genotypes has never been formally assessed. 
 
We conducted a systematic review and meta-analysis to estimate the sensitivity and specificity of 
HBcrAg test to diagnose three clinically important HBV DNA thresholds (≥2,000, ≥20,000, and 
≥200,000 IU/ml) determined by the reference NAT assays in patients with CHB. We also conducted 
subgroup analyses according to viral genotypes. To synthesize these estimates, we sought individual 
participant data (IPD) from each eligible study, because aggregate data at these specific HBV DNA 
cut-offs were rarely reported in the previous literatures with few exceptions.14  
 
Materials and Methods 
Our systematic review followed a protocol registered at PROSPERO (CRD42017055440), and was 
reported according to the Preferred Reporting Items for a Systematic Review and Meta-Analysis of 
Individual Participant Data (The PRISMA-IPD) guidelines.17 This meta-analysis was exempt from 
ethical approval because the analysis only used anonymized data, and all the original studies had 






Data Sources and Searches 
Ovid Medline, Ovid Embase, Scopus, and Web of Science were searched from 1st January, 2000 to 
27th June, 2018. Following search terms and their variations were used: hepatitis B, core, antigen, and 
HBcrAg (see Supplementary Document 1 for detailed search strategy). A manual search through 
bibliographies was also conducted. Three authors (KY, AD, and SFF) independently screened the 
titles and abstracts of identified citations using pre-specified eligibility criteria. Full-text reading was 
performed for the potentially eligible citations to examine their eligibility. Disagreements were 
resolved by another reviewer (YS).  
 
Study Selection 
Studies that measured both HBV DNA and HBcrAg levels using the same blood sample from the 
same individuals with CHB were eligible for the analysis. These individuals needed to be stratified by 
the presence of concurrent antiviral treatment. Single case reports, letters, reviews, conference 
abstracts, and those included only patients with hepatocellular carcinoma (HCC) were excluded. Study 
inclusion was not restricted by language, sample size or participants’ age. 
 
Data Extraction and Quality Assessment  
Two authors (KY and SFF) independently extracted the following information using a pre-piloted 
standardized form: study design, settings, objectives, number of participants, participants’ selection 
methods and criteria, participants’ characteristics, type and condition of samples used to measure 
HBcrAg and HBV DNA, and assay methods. Citations in foreign language were translated and the 
data was extracted by native speakers using the same data extraction sheet. Unless all the necessary 
individual-level data were reported in the original article, corresponding authors of the eligible papers 
were systematically invited to be a co-investigator of the current work by e-mail, and asked to provide 
the IPD using a standardized spreadsheet for the following variables: age, sex, HBcrAg levels, HBV 
DNA levels, NAT type, HCC status, concurrent anti-HBV treatment, types and conditions of samples, 





four weeks, a reminder was sent. Studies without IPD were excluded from our analysis. The IPD were 
systematically examined for their integrity, including consistency and completeness. The risk of bias 
and quality assessment were performed using a tool adapted from the Quality Assessment of 
Diagnostic Accuracy Studies (QUADAS-2),18 which is available in the Supplementary Document 2.  
 
Data Synthesis and Analysis 
Because some study centers generated multiple eligible studies, and these studies often used the data 
from the same individuals more than once, general characteristics of the IPD were presented by study 
center, rather than by each study, to avoid double counting. For the quantitative analysis, the 
quantification limit of the HBcrAg assay minus 0.1 (i.e., 2.9 log U/ml) was assigned to samples with 
undetectable HBcrAg. Virological characteristics were compared between those with and without 
antiviral therapy using Wald test with robust standard error to account for clustering within the centers. 
The linear correlation between HBcrAg levels and HBV DNA levels was evaluated quantitatively 
using Pearson’s correlation coefficient, and visually using a locally weighted scatter plot smoothing 
(LOWESS). One step approach was used for the meta-analysis in which the IPD from all studies were 
modelled simultaneously while taking account for clustering of patients within the study centers.19 The 
capabilities of HBcrAg to correctly discriminate serum HBV DNA levels at the cut-off of ≥2,000, 
≥20,000, and ≥200,000 IU/ml were evaluated by using the receiver operating characteristic (ROC) 
curve. Our primary outcome measure was pooled area under the ROC curve (AUROC), which was 
obtained by the parametric two-stage model developed by Alonzo and Pepe20 to account for the 
clustering within the centers. To estimate the 95% confidence interval (95% CI) of the AUROC, 1,000 
bootstrap replications were used. Each non-treated individual was randomly allocated to derivation or 
validation cohort (1:1). Using the derivation set, the optimal HBcrAg cut-offs were determined to 
minimize the absolute difference between sensitivity and specificity. These cut-offs were then applied 
to the validation set to obtain the pooled sensitivity and specificity. The proportion correctly classified 
was computed as below: disease prevalence * sensitivity + (1 – disease prevalence) * specificity. 
Subgroup analyses were conducted using the whole non-treated cohort. To compare the AUROC 





HCV/HIV/HDV co-infection, the interaction test by Altman and Bland was conducted when 
comparing two groups,21 and one-way analysis of variance when comparing more than two groups.22 




A total of 10,863 titles and abstracts were screened, and 227 studies were assessed in full text for their 
eligibility (Figure 1). Of 74 studies that met our criteria, IPD were finally obtained for 60 studies 
(81%). The IPD were either reported in the original articles (4 studies) or shared by the corresponding 
authors (56 studies). After excluding 87 patients with HCC and 586 patients with incomplete 
information, the analysis finally included a total of 10,397 IPD: 5,591 patients without antiviral 
therapy (50 studies from 23 centers) and 4,806 patients under antivirals (39 studies from 19 centers). 
The vast majority of patients under treatment (94%, n=4,511) received nucles(t)ide analogues (NA), 
and only few (6%, n=278) had interferon-based therapy (IFN). Characteristics of the included studies 
by study center are summarized in Table 1. The study was conducted in Asia (n=50), Europe (n=9), 
and Africa (n=1). All the studies used serum samples to measure HBcrAg with a chemiluminescent 
immunoassay (Lumipulse®, Fujirebio Inc., Tokyo, Japan). HBV DNA was quantified by RT-PCR in 
majority of samples (10,103; 98%), using the following assays: COBAS TaqMan (n=8,044) and 
Amplicor (n=797) (Roche Diagnostics); RealTime/AccuGene (n=400) (Abbott); and in-house methods 
(n=862). The rest (157 samples; 2%) was tested using transcription mediated amplification (TMA): 
TMA, Chugai Diagnostics (n=104); and DNA Probe FR-HBV, Fujirebio (n=53). 
 
Characteristics of the included studies 
Table 2 presents the patients’ characteristics by the concurrent anti-HBV treatment. Median age 
(years) was 45 (IQR: 34-57) in non-treated and 56 (45-64) in treated group. HBeAg was positive in 
37% of non-treated and 31% of treated group. Whilst proportion with undetectable HBV DNA was 
significantly higher in treated (64%) than in non-treated (12%, p<0.001), the proportion with 





with undetectable HBV DNA, only the minority had detectable HBcrAg in non-treated group (27%, 
189/692), but the majority had detectable HBcrAg in treated group (69%, 2,114/3,080, p=0.002).  
 
Risk-of-Bias Assessment 
The risk-of-bias is summarized for all 60 included studies (Supplementary Figure 1) and for each 
study (Supplementary Figure 2). Only 16 studies enrolled a consecutive/random sample. Some studies 
restricted participants to be HBeAg-positive (n=13), HBeAg-negative (n=7), having high viral load 
(n=9), or low viral load (n=5), which raised concern about applicability of these studies. Except 13 
studies, the objective of the original work was not to assess the correlation between HBcrAg and HBV 
DNA. No study, but one,14 mentioned whether those examined HBcrAg were blinded to the results of 
HBV DNA, and vice versa.  
 
Correlation between serum HBcrAg levels and HBV DNA levels 
Figure 2 presents the scatter plot of HBcrAg and HBV DNA with the LOWESS in patients without 
antiviral therapy. The correlation was observed irrespective of viral genotypes. Pearson’s correlation 
coefficient was 0.84 for all untreated subjects, and 0.83, 0.84, 0.83, 0.85, and 0.82 for genotype A, B, 
C, D, and E, respectively. The scatter plot of HBcrAg and HBV DNA in non-treated patients by 
HBeAg positivity is presented in the Supplementary Figure 3. In contrast with those without antiviral 
treatment, the correlation was poor in patients under treatment (r=0.54) (Supplementary Figure 4), and 
therefore the subsequent analyses were not performed in this group. 
 
Performance of HBcrAg to diagnose high viral load in non-treated patients 
In patients without antiviral therapy, the pooled AUROC was: 0.88 (95% CI: 0.83-0.94) for the 
diagnosis of HBV DNA levels of ≥2,000 IU/ml; 0.95 (0.93-0.97) for ≥20,000 IU/ml; and 0.96 (0.94-
0.98) for ≥200,000 IU/ml (Figure 3). To obtain the optimal cut-offs, the non-treated cohort was 
randomly divided into two: derivation and validation set. These groups had similar characteristics 
(Supplementary Table 1). The optimal cut-offs (log U/ml) were 3.6, 4.5, and 5.3 to diagnose HBV 





applying these to the validation set, the sensitivity, specificity, and the proportion correctly classified 
were: 85.2%, 84.7% and 85.0% for ≥2,000 IU/ml, 90.4%, 91.9% and 91.1% for ≥20,000 IU/ml, and 
91.8%, 90.5% and 91.1% for ≥200,000 IU/ml, respectively (Table 3). 
 
Subgroup analysis in non-treated patients 
The pooled AUROCs did not vary according to the sex, age groups (<30 or ≥30 years), study regions 
(Asia, Europe, or Africa), HBV genotypes (A/B/C/D/E), HCV, or HDV co-infection (Table 3). Across 
the different viral genotypes, the AUROCs were constantly ≥0.80, ≥0.93 and ≥0.95 to diagnose 
viremia of ≥2,000, ≥20,000 and ≥200,000 IU/ml, respectively. In 1,134 women of reproductive age 
(15-49 years), the AUROC was 0.98 (95% CI: 0.96-1.00) with a sensitivity of 94.1% and a specificity 
of 89.5% to diagnose HBV DNA thresholds requiring peripartum antiviral prophylaxis (i.e., viral load 
≥200,000 IU/ml). A post-hoc analysis was performed in the women of reproductive age for the 
performance of HBeAg; although mean viral load (± standard deviation) was much higher in HBeA-
positive women (7.18 ± 1.81 log IU/ml) than in HBeAg-negative women (3.07 ± 1.90 log IU/ml), the 
AUROC of HBeAg was 0.76 (95% CI: 0.64-0.88) to discriminate between high and low viral loads at 
the cut-off level of ≥200,000 IU/ml. 
 
The performance of HBcrAg to diagnose viral load ≥2,000 IU/ml differed according to the HBeAg 
sero-status (P for interaction for AUROC <0.01); the sensitivity and specificity were 97.9% and 
23.4% in HBeAg-positive and 66.0% and 87.2% in HBeAg-negative group, respectively. The low 
specificity in HBeAg-positive group and low sensitivity in HBeAg-negative group, however, had 
minimal impact on the overall misclassification in each sub-group. The high false positive rate 
(76.6%) in HBeAg-positive group was offset by the small prevalence (3.9%) of low viremia (<2,000 
IU/ml) in this group, resulting in 95.0% of HBeAg-positive patients being correctly classified by 
HBcrAg (Table 3). Similarly, low sensitivity (66.0%) in HBeAg-negative group was relevant in only 
the minority (37.0%) of those with high viremia (≥2,000 IU/ml), which led to 79.4% of HBeAg-







This systematic review successfully obtained the IPD from the majority of eligible studies (81%, 
60/74). This allowed us to synthesize robust estimates using large, well-characterized datasets with 
varying virological and epidemiological background. Despite the heterogeneity among reference 
assays used to quantify HBV DNA across the studies, we found: (i) a close correlation between 
HBcrAg and HBV DNA and excellent performance of HBcrAg levels to indicate clinically important 
viral load irrespective of HBV genotypes in CHB patients without antiviral therapy; and (ii) lack of 
correlation in those treated with antivirals.   
 
In high-income countries, HBcrAg is increasingly recognized as a surrogate marker for cccDNA 
amount and its transcriptional activity, and useful tool to monitor the treatment response.16,23,24 
Although quantification of intrahepatic amount of cccDNA, a key genomic form responsible for the 
persistence of infection, should be highly informative to manage CHB patients, this requires liver 
biopsy and therefore cannot be routinely performed. Instead, serum HBV DNA has been clinically 
used as a routine biomarker for HBV replication. In patients under antiviral therapy, however, 
discrepancies become apparent between intrahepatic cccDNA and serum HBV DNA levels; while 
nucleos(t)ides analogues inhibit reverse transcription and almost invariably lead to undetectable serum 
HBV DNA, intrahepatic cccDNA often persists despite long-term treatment.25 Next commonly used 
marker for HBV replication is quantification of serum HBsAg. However, its correlation with cccDNA 
is also limited, particularly in HBeAg-negative patients, because HBsAg is derived not only from 
intrahepatic cccDNA but also from HBV DNA sequences integrated into the host genome.26 Contrary 
to these conventional biomarkers, a close correlation between serum HBcrAg and intrahepatic 
cccDNA has been observed in treatment-naïve patients,10,11,15,16,27–29 and also in those who underwent 
anti-HBV therapy in whom a magnitude of reduction in HBcrAg is well correlated with that of 
cccDNA.10,11,15,27 Not surprisingly, in this meta-analysis, poor correlation was confirmed between 
HBV DNA and HBcrAg in patients under treatment, and the majority (69%) of the treated patients 





the previous findings, and support the utility of serum HBcrAg as an endpoint for novel anti-HBV 
drugs aiming at a complete cure of HBV infection.16,24 
 
In addition to its great potential as a tool to monitor patients under treatment, serum HBcrAg may also 
be useful to indicate clinically important HBV DNA levels in treatment-naïve patients, as suggested 
by our meta-analysis. This may support its use as an alternative to NAT to select patients in need of 
antiviral therapy subsequent to a positive HBsAg screening result. A recent African study 
demonstrated a sensitivity of 96.6% and specificity of 85.8% for a simplified treatment algorithm 
using HBcrAg to indicate the treatment eligibility determined by the reference tests including HBV 
DNA quantification.14 Furthermore, some studies suggested that HBcrAg might be even more accurate 
than HBV DNA levels to predict liver disease progression in treatment-naïve patients. A long-term 
follow-up of a large Japanese cohort of CHB patients without anti-HBV treatment found that 
quantification of HBcrAg was superior to serum viral load to predict the development of HCC,30 and 
cirrhosis.31 In a recent study in Taiwan also confirmed the independent association between serum 
HBcrAg levels and HCC development.32 
 
A recent advent of inexpensive automated point-of-care PCR assays, such as GeneXpert, may help to 
overcome the limited access to the conventional NAT assays in LMICs. To further decentralize 
clinical staging of CHB, there is a need to develop an assay fully adapted to resource-limited primary 
healthcare settings without air-conditioning or uninterrupted electricity supply.33 Indeed, the 
development of an inexpensive rapid test based on lateral-flow technology to detect HBcrAg is 
currently ongoing, and its evaluation will be performed in LMICs. Lowering the detection limit for 
such a test may be less relevant; for example, a rapid test detecting high HBcrAg levels of ≥5.3 log 
U/ml (equivalent to viral load of ≥200,000 IU/ml) should be extremely useful at antenatal care to 
select pregnant women for anti-HBV therapy to prevent mother-to-child transmission, because of its 
high clinical sensitivity (94.1%) and specificity (89.5%) to indicate HBV DNA levels at risk of 
immunoprophylaxis failure. In addition, analytical sensitivity of HBcrAg has been recently improved 





may lead to future development of rapid test targeting lower thresholds equivalent to viral loads of 
≥2,000 or ≥20,000 IU/ml. 
 
As a limitation, most included studies are from high-income countries and mainly from Asia with an 
over-representation of HBV genotypes B and C. Studies are needed from other geographical regions, 
particularly those from resource-limited countries. Second, clinical sensitivity of HBcrAg for viral 
load ≥2,000 IU/ml was moderate (66.0%) in HBeAg-negative patients. This may have an impact in 
countries where the prevalence of HBeAg is low (e.g., in Africa). Nevertheless, by applying the data 
from a large population-based study in West Africa (96.7% of adults with CHB infection being 
negative for HBeAg, and 8.5% of those negative for HBeAg had viral load ≥2,000 IU/ml),34 the use of 
HBcrAg would still correctly classify 85.4% of HBeAg-negative African people for diagnosing 
≥2,000 IU/ml. New version of the HBcrAg assay with an improved analytical sensitivity (2.1 log 
U/mL) will be available in near future, and this should further increase the diagnostic sensitivity. 
Moreover, there are recent publications supporting the usefulness of HBcrAg in HBeAg-negative 
patients.35,36 Third, we could not assess the performance of HBcrAg to indicate treatment eligibility 
per se. The treatment eligibility criteria, apart from those for pregnant women for the prevention of 
mother-to-child transmission, are composed of a combination of multiple factors, and HBV viral load 
merely represents one of these. In this study, we did not seek individual participant data for liver 
inflammation or fibrosis. Forth, the included studies suffered from the risk-of-bias. None, but one, 
reported that the index test was performed by staff blinded to the result of the reference test, and vice 
versa, because most of the original studies were not designed to evaluate the performance of HBcrAg 
to diagnose HBV viral load.  
 
LMICs account for the highest HBV burden, yet, face enormous challenges in scaling up treatment 
services with the limited access to NAT assays. HBcrAg, an attractive alternative to HBV DNA RT-
PCR, has potential to contribute to the global elimination goals. Further studies, particularly those 
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Figure 1. Flow diagram of study selection 
 
Figure 2. Correlation between HBcrAg & HBV DNA levels with locally weighted scatter plot 
smoothing (LOWESS) in patients without treatment, by viral genotypes 
 
Figure 3. Receiver operating characteristic curves for HBcrAg to diagnose clinically important HBV 
DNA levels (dash: ≥2,000 IU/ml; short dash: ≥20,000; solid: ≥200,000) 
